Overview

Study to Assess the Efficacy and Safety of Rilonacept Treatment in Participants With Recurrent Pericarditis

Status:
Active, not recruiting
Trial end date:
2022-05-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study was to assess the efficacy of rilonacept treatment in participants with recurrent pericarditis.
Phase:
Phase 3
Details
Lead Sponsor:
Kiniksa Pharmaceuticals (UK), Ltd.
Kiniksa Pharmaceuticals, Ltd.
Treatments:
Rilonacept